WALTHAM,
Mass., Feb. 25, 2025 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology
company advancing best-in-class antibody engineering, dose
optimization, and rational therapeutic combinations for the
treatment of Inflammatory Bowel Disease ("IBD") and other
immune-mediated diseases, today announced that management will
participate in the following upcoming investor conferences:
Event: TD Cowen 45th Annual Healthcare
Conference
Format: Fireside chat and 1x1 meetings
Date/Time: Tuesday, March 4,
2025 at 3:10pm ET
Location: Boston, MA
Event: Jefferies Biotech on the Beach
Summit
Format: 1x1 meetings
Date: Tuesday, March 11,
2025
Location: Miami, FL
Live audio webcasts and replays of the TD Cowen fireside event
will be available on the Spyre investor events website at
https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a
biotechnology company that aims to create next-generation
inflammatory bowel disease (IBD) and other immune-mediated disease
products by combining best-in-class antibody engineering, dose
optimization, and rational therapeutic combinations. Spyre's
pipeline includes extended half-life antibodies targeting α4β7,
TL1A, and IL-23. For more information, visit Spyre's website at
www.spyre.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-march-investor-conferences-302383597.html
SOURCE Spyre Therapeutics, Inc.
